1. Home
  2. SOS vs GOVX Comparison

SOS vs GOVX Comparison

Compare SOS & GOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SOS Limited

SOS

SOS Limited

HOLD

Current Price

$1.40

Market Cap

10.7M

Sector

Finance

ML Signal

HOLD

Logo GeoVax Labs Inc.

GOVX

GeoVax Labs Inc.

HOLD

Current Price

$0.37

Market Cap

12.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SOS
GOVX
Founded
2004
2001
Country
China
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
12.2M
IPO Year
2017
N/A

Fundamental Metrics

Financial Performance
Metric
SOS
GOVX
Price
$1.40
$0.37
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$7.00
AVG Volume (30 Days)
43.4K
538.2K
Earning Date
09-26-2025
11-13-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$260,505,000.00
$3,353,560.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
134.43
8.52
52 Week Low
$1.02
$0.37
52 Week High
$9.62
$2.75

Technical Indicators

Market Signals
Indicator
SOS
GOVX
Relative Strength Index (RSI) 47.24 36.87
Support Level $1.29 $0.37
Resistance Level $1.56 $0.41
Average True Range (ATR) 0.11 0.03
MACD 0.04 0.01
Stochastic Oscillator 53.44 12.10

Price Performance

Historical Comparison
SOS
GOVX

About SOS SOS Limited

SOS Ltd is a multifaceted company that leverages the power of data to provide marketing solutions, while also participating in the burgeoning fields of blockchain and cryptocurrency operations, as well as commodity trading. Its product offerings are diversified across four main areas: commodity trading, insurance marketing, cryptocurrency mining, and other services. The company has three reporting segments: Commodity trading, Cryptocurrency mining, and Others. Key revenue is generated from Commodity trading.

About GOVX GeoVax Labs Inc.

Geovax Labs Inc is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using novel proprietary platforms. GeoVax's product pipeline includes ongoing human clinical trials for a next-generation COVID-19 vaccine and a gene-directed therapy against head and neck cancers. Additional research and development programs include preventive vaccines against Monkeypox (MPox), hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan, Marburg, and Lassa), and Zika virus, as well as immunotherapies for multiple solid tumors. The Company's key clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine.

Share on Social Networks: